
IV and topical TXA superior to placebo for hematological outcomes after PLIF

IV and topical TXA superior to placebo for hematological outcomes after PLIF
Intravenous Administration of Tranexamic Acid Significantly Reduces Visible and Hidden Blood Loss Compared with Its Topical Administration for Double-Segment Posterior Lumbar Interbody Fusion: A Single-Center, Placebo-Controlled, Randomized Trial
World Neurosurg. 2019 Feb;122:e821-e827.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
150 patients with lumbar degenerative disease and scheduled for a posterior lumbar interbody fusion procedure were randomized to receive intravenous TXA, topical TXA or placebo for blood loss. Outcomes of interest included hemoglobin, hematocrit and fibrinogen levels, prothrombin time, extubation time, hospital length of stay, post-operative Visual Analog Scale (VAS), intra-operative blood loss, d...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Join the Conversation
Please Login or Join to leave comments.